The New York Times "The Morning" (March 28, 2022)addressed the issue of the immunocompromised, who have ineffective protection with Covid-19 protection. There is a drug called Evusheld, developed by AstraZeneca, but no one seems to know about it. I blogged about it right after I received my two injections. It provides months of protection. 850,000 people could get added protection but about 80 percent of the doses are sitting in hospitals, warehouses, and pharmacies unused.
Why is this happening? It is because no one knows about it. Or no one knows who qualifies.
We need a plan, people!
Dr. Daniel Griffin talks about Evusheld and Paxlovid every single week in his weekly update on TWIV.
ReplyDeleteThat is wonderful. I will make a point of checking in on the updates.
DeletePaxlovid, an anti-viral med, is recommended by NIH for cancer patients like me who get infected with Covid. The five days you are taking the prescription, you have to be off Ibrutinib and also any statins.